Comparison of the Subcutaneous Absorption of Insulin Glargine (Lantus®) and NPH Insulin in Patients with Type 2 Diabetes

Hormone and Metabolic Research

Volumn 35, Issue 7, 2003, Pages 434-438

  Luzio, S D ^a   Beck, P ^a   Owens, D R ^a  

^a LLANDOUGH HOSPITAL   (United Kingdom)

Author keywords

Absorption; Insulin; Type 2 diabetes

Indexed keywords

C PEPTIDE; GLIBENCLAMIDE; GLICLAZIDE; GLIPIZIDE; GLUCOSE; INSULIN; INSULIN GLARGINE; IODINE 125; ISOPHANE INSULIN; METFORMIN;

ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; BODY MASS; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DISEASE DURATION; DOUBLE BLIND PROCEDURE; DRUG ABSORPTION; DRUG TOLERABILITY; GLUCOSE BLOOD LEVEL; HEADACHE; HUMAN; HYPOGLYCEMIA; INSULIN BLOOD LEVEL; NON INSULIN DEPENDENT DIABETES MELLITUS; PHARMACODYNAMICS; PRIORITY JOURNAL; RADIOACTIVITY; RANDOMIZED CONTROLLED TRIAL; SINGLE DRUG DOSE; STATISTICAL ANALYSIS; VERTIGO;

ADULT; AGED; BLOOD GLUCOSE; C-REACTIVE PROTEIN; CROSS-OVER STUDIES; DIABETES MELLITUS, TYPE 2; DOUBLE-BLIND METHOD; HALF-LIFE; HUMANS; HYPOGLYCEMIC AGENTS; INJECTIONS, SUBCUTANEOUS; INSULIN; INSULIN, ISOPHANE; IODINE RADIOISOTOPES; MIDDLE AGED; SCINTILLATION COUNTING; SKIN ABSORPTION;

EID: 0242721280     PISSN: 00185043     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2003-41625     Document Type: Article

References (18)

1. UKPDS. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998; 352: 837-853
2. Turner R, Cull C, Frighi V, Holman R. Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus: progressive requirement for multiple therapies (UKPDS 49). UK Prospective Diabetes Study (UKPDS) Group. JAMA 1999; 281: 2005-2012
3. Yki-Jarvinen H, Ryysey L, Nikkila K, Tulokas T, Vanamo R, Heikkila M. Comparison of bedtime insulin regimens in patients with type 2 diabetes mellitus. Ann Intern Med 1999; 130: 389-396
4. Heinemann L, Linkeschova R, Rave K, Hompesch B, Sedlak M, Heise T. Time-action profile of the long-acting insulin analog insulin glargine (HOE901 ) in comparison with those of NPH insulin and placebo. Diabetes Care 2000; 23: 644-649
5. Ciofetta M, Lalli C, Del Sindaco PD, Torlone E, Pampanelli S, Mauro L, Chiara DL, Brunetti P, Bolli GB. Contribution of postprandial versus interprandial blood glucose to HbA1c in type 1 diabetes on physiologic intensive therapy with lispro insulin at mealtime. Diabetes Care 1999; 22: 795-800
6. Owens DR. Human insulin: clinical pharmacological studies in normal man. In: Owens DR (ed). Lancaster: MTP Press, 1986
7. Bolli G, DiMarchi R, Park G, Pramming S, Koivisto VA. Insulin analogues and their potential in the management of diabetes mellitus. Diabetologia 1999; 42: 1151-1167
8. Binder C, Lauritzen T, Faber O, Pramming S. Insulin pharmacokinetics. Diabetes Care 1984; 7: 188-199
9. Lepore M, Pampanelli S, Fanelli C, Porcellati F, Bartocci L, di Vincenzo A, Cordoni C, Costa E, Brunetti P, Bolli GB. Pharmacokinetics and pharmacodynamics of subcutaneous injection of long-acting human insulin analog glargine, NPH insulin, and ultralente human insulin and continuous subcutaneous infusion of insulin lispro. Diabetes 2000; 49: 2142-2148
10. Rosskamp RH, Park G. Long-acting insulin analogs. Diabetes Care 1999; 22: B109-B113
11. Hildebrandt P. Subcutaneous absorption of insulin in insulin-dependent diabetic patients. Influence of species, physio-chemical properties of insulin and physiological factors. Dan Med Bull 1991; 38: 337-346
12. Heinemann L, Linkeschowa R, Rave K, Hompesch B, Sedlak M, Heise T. Time-action profile of the long-acting insulin analog insulin glargine (HOE901) in comparison with those of NPH insulin and placebo. Diabetes Care 2000; 23 (5): 644-649
13. Owens D, Coates P, Luzio S, Tinbergen JP, Kurzhals R. Pharmacokinetics of [125]l- labelled insulin glargine (HOE 901) in healthy men. Diabetes Care 2000; 23: 813-819
14. Gliemann J, Sonne O, Linde S, Hansen B. Biological potency and binding affinity of monoiodoinsulin with iodine in tyrosine A14 or tyrosine A19. Biochem Biophys Res Commun 1979; 87: 1183-1190
15. Ferraiolo BL. Protein pharmacokinetics and metabolism. Pharmaceutical Biotechnology, Vol. 1. In: Ferraiolo BL, Mohler MA, Glof CA (eds). New York: Plenum Publication Corporation, 1992
16. Cryer P. Hypoglycaemia is the limiting factor in the management of diabetes. Diabetes Metab Res Rev 1999; 15: 42-46
17. Matthews D, Pfeiffer C. A new long-acting insulin (HOE901) demonstrates less nocturnal hypoglycaemia when compared with protamine insulin in a clinical trial. Diabetologia 1998; 41 : A245 (Abstract 948)
18. Yki-Jarvinen H, Dressler A, Ziemen M. Less nocturnal hypoglycemia and better post-dinner glucose control with bedtime insulin glargine compared with bedtime NPH insulin during insulin combination therapy in Type 2 diabetes. Diabetes Care 2000; 23: 1130-1136